Thick cutaneous malignant melanoma: A reappraisal of prognostic factors

Melanoma Research

Volumn 10, Issue 2, 2000, Pages 153-164

  Massi, D ^a   Borgognoni, L ^b   Franchi, A ^a   Martini, L ^b   Reali, U M ^b   Santucci, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Malignant melanoma; Mitotic rate; Prognosis; Thick lesions; Thickness; Tumour invasive front; Ulceration

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; ULCER;

EID: 0034024007     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010020-00008     Document Type: Article

References (37)

1. 1. Van der Esch EP, Cascinelli N, Preda F, Morabito A, Bufalino R. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer 1981; 48: 1668-1673.
2. 2. Day CL Jr, Lew RA, Mihm MC Jr, Sober AJ, Harris MN, Kopf AW, Fitzpatrick TB, Harrist TJ, Golomb FM, Postel A, Hennessey P, Gumport SL, Raker JW, Malt RA, Cosimi AB, Wood WC, Roses DF, Gorstein F, Rigel D, Friedman RJ, Mintzis MM, Grier RW. A multivariate analysis of prognostic factors for melanoma patients with lesions ≥ 3.65 mm in thickness. Ann Surg 1982; 195: 44-49.
3. 3. Balch CM, Soong S, Shaw HM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM. Cutaneous Melanoma. Philadelphia, JB Lippincott, 1992: 165-187.
4. 4. Schneebaum S, Briele HA, Walker MJ, Greager J, Wood DK, Ronan SG, Patel MK, Das Gupta TK. Cutaneous thick melanoma. Prognosis and treatment. Arch Surg 1987; 122: 707-711.
5. 5. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45-49.
6. 6. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994; 80: 188-197.
7. 7. Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R, Rahman I, Wortzel H, Marghoob AA, Bart RS. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997; 80: 1426-1431.
8. 8. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997; 24: S2-S7.
9. 9. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45: 3012-3017.
10. 10. Blessing K, McLaren KM, McLean A, Davidson P. Thick malignant melanomas (> 3 mm Breslow) with good clinical outcome: a histological study and survival analysis. Histopathology 1991; 18: 143-148.
11. 11. Harrist TJ, Rigel DS, Day CL Jr, Sober AJ, Lew RA, Rhodes AR, Harris MN, Kopf AW, Freedman RJ, Golomb FM, Cosimi AB, Gorstein F, Malt RA, Wood WC, Postel A, Hennessey P, Gumport SL, Roses DF, Mintzis MM, Waker JW, Fitzpatrick TB, Mihm MC Jr. 'Microscopic satellites' are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984; 53: 2183-2187.
12. 12. Evans AT, Blessing K, Orrell JM, Grant A. Mitotic indices, anti-PCNA immunostaining, and AgNORs in thick cutaneous melanomas displaying paradoxical behaviour. J Pathol 1992; 168: 15-22.
13. 13. Rivers JK, McCarthy SW, Shaw HM, Jones AS, Glasziou P, Doran TJ, McCarthy WH. Patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses. Histopathology 1991; 18: 339-346.
14. 14. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53 and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57-63.
15. 15. Mauri MF, Boi S, Micciolo R, Cristofolini M, Dalla Palma P. Morphometric analysis in prognostic evaluation of stage I cutaneous melanomas. Anal Quant Cytol Histol 1997; 19: 311-315.
16. 16. Mossbacher U, Knollmayer S, Binder S, Steiner A, Wolff K, Pehamberger H. Increased nuclear volume in metastasizing 'thick' melanomas. J Invest Dermatol 1996; 106: 437-440.
17. 17. Ross DA, Wilson CD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg 1998; 85: 46-51.
18. 18. Sobin LH, Wittekind, eds. TNM Classification of Malignant Tumours, 5th edn. New York: Wiley-Liss, Inc., 1997: 118-121.
19. 19. Clark WH Jr, Fromm L, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-727.
20. 20. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
21. 21. McGovern VJ, Shaw HM, Milton GW. Prognostic significance of polypoid configuration in malignant melanoma. Histopathology 1983; 7: 663-672.
22. 22. Clark WH Jr, Elder DE, DuPont G IV, Braitman LE, Trock BJ, Schultz, D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893-1904.
23. 23. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978; 114: 871-873.
24. 24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. 25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-202.
26. 26. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanomas (≤ 1.5 mm): identification of risk factors indicative of progression. Cancer 1999; 85: 1067-1076.
27. 27. Sondergaard K, Schou G. Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases. Virchows Arch [Pathol Anat] 1985; 406: 179-195.
28. 28. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78: 427-432.
29. 29. Keefe M, MacKie RM. The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumor: no evidence for steps in risk. Br J Cancer 1991; 64: 598-602.
30. 30. Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defening cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol 1997; 50: 1201-1210.
31. 31. Jass JR, Atkins WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP. The grading of rectal cancer: historical perspective and a multivariate analysis of 447 cases. Histopathology 1986; 10: 437-459.
32. 32. Thorn M, Pontén F, Bergstrom R, Sparén P, Adami HO. Clinical and histopathological predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994; 86: 761-769.
33. 33. Masback A, Westerdahl J, Ingvar C, Ollson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden in 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer 1997; 79: 275-283.
34. 34. Mascaro JM, Castro J, Castel T, Lecha M, Gratacos R, Mascaro JM Jr. Why do melanomas ulcerate? J Cutan Pathol 1984; 11: 269-273.
35. 35. Ronan SG, Han MC, Das Gupta TK. Histologic prognostic indicators in cutaneous malignant melanoma. Semin Oncol 1988; 15: 558-565.
36. 36. Worth AJ, Gallager RP, Elwood JM, Jang PC, Lamb C, Spinelli JJ, Wood WS, Threlfall WJ, Hill GB. Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer 1989; 43: 370-375.
37. 37. Henaan PJ, English DR, Holman CDJ, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in western Australia in 1975/1976 and 1980/1981. Cancer 1991; 68: 2079-2087.